ORIGINAL RESEARCH article
Front. Neurol.
Sec. Movement Disorders
Clinical Analysis of the Development of Guillain-Barré Syndrome During Bortezomib Treatment for Multiple Myeloma
Provisionally accepted
- 1Fujian Institute of Hematology, Fuzhou, China
- 2Fujian Provincial Key Laboratory on Hematology, Fuzhou, China
- 3Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
- 4Department of Neurology, Yidu Central Hospital of Weifang, Qingzhou, China
- 5Department of Intensive Care Medicine, Yidu Central Hospital of Weifang, Qingzhou, China
- 6Department of Hematology, Yidu Central Hospital of Weifang, Qingzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The development of Guillain-Barr é syndrome (GBS) during bortezomib treatment for multiple myeloma (MM) is rare. Clinical vigilance regarding this serious adverse event is imperative for timely diagnosis and management. Methods: We conducted a retrospective review of the hospital's health information system (HIS) and report three cases of GBS that occurred during bortezomib-based treatment in patients with MM. A retrospective analysis of the patients' clinical presentations, diagnostic processes, treatments, and prognoses was conducted. Additionally, a literature search was performed by using the keywords "multiple myeloma", "bortezomib", "GBS", and "polyneuropathy" in the PubMed and China National Knowledge Infrastructure (CNKI) databases, which yielded 30 relevant published cases for review. Results: A total of 33 cases were included in the analysis. The VRD regimen (bortezomib, lenalidomide, and dexamethasone) appeared to be associated with the development of GBS in patients with IgA-type MM, whereas the VTD regimen (bortezomib, thalidomide, and dexamethasone) was more commonly associated with IgG-type MM. Intravenous immunoglobulin (IVIG) and plasma exchange represented the main first-line treatments, and most of the patients achieved varying degrees of neurological recovery within a median of 4.5 months (range: 3 weeks to 21 months). Conclusion: Neurological examination, cerebrospinal fluid analysis revealing albuminocytologic dissociation, and nerve conduction studies were helpful for diagnosing GBS. Prompt treatment with IVIG and/or plasma exchange can significantly improve patient outcomes.
Keywords: Bortezomib, GBS, Multiple Myeloma, immune treatment, prognosis
Received: 05 Jun 2025; Accepted: 07 Nov 2025.
Copyright: © 2025 Li, Chen, Liu, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiang-Lei Chen, cxl20131003@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.